ImportantUpdates
Biocon's US subsidiary secured FDA approval for Yesintek® (ustekinumab-kfce) single-dose autoinjectors.
Biocon LimitedBIOCON · Filed with the exchange
This new delivery format expands patient treatment options for autoimmune diseases, significantly strengthening Biocon's immunology presence in the US market.
No comments yet. Be the first.